BRD4/NAMPT-IN-1

BRD4/NAMPT-IN-1 (Compound A2) shows strong inhibitory effects on NAMPT and BRD4 (IC50=35 nM (NAMPT) and 58 nM (BRD4) ) . BRD4/NAMPT-IN-1 inhibits the growth and migration of hepatocellular carcinoma cells and promotes apoptosis. BRD4/NAMPT-IN-1 also shows potent anticancer effects in HCCLM3 xenograft mouse model, with no obvious toxic effects[1].

Product Specifications

CAS Number

[3049218-28-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Epigenetic Reader Domain; NAMPT

Type

Reference compound

Related Pathways

Epigenetics; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/brd4-nampt-in-1.html

Purity

99.45

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC(C=C1)=CC=C1C2=N[C@@H](CC(NCCCNC(/C=C/C3=CN=CC=C3)=O)=O)C4=NN=C(C)N4C5=C2C(C)=C(C)S5

Molecular Formula

C30H30ClN7O2S

Molecular Weight

588.12

Precautions

H302, H315, H319, H335

References & Citations

[1]Yin C, et al. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma. Eur J Med Chem. 2024 May 5;271:116444.